What happens when clinical care directly informs scientific discovery? This episode sees EACR award winners Charlie Swanton, Ayelet Erez and Daniel Kirschenbaum reflect on what drew them to pursuing cancer research alongside patient care, how bedside experiences guide lab investigations, and what it takes to turn a promising finding into real clinical progress. We also touch on recent breakthroughs in their work, and the biggest changes they’ve witnessed in the field.

🔗 Access transcripts for all our episodes at magazine.eacr.org/podcast

Professor Xin Lu, Director of the Ludwig Institute for Cancer Research, Oxford Branch, and keynote speaker at EACR 2026, talks about her scientific journey shaped by the early, influential studies of P53 and its role as a central tumour suppressor.

Tracing her journey from early training in China to landmark work in the UK, the conversation explores how fundamental questions about DNA damage, cell death, and oncogene stress led to the discovery of the ASPP family of P53 regulators.

The discussion further expands into the concept of cellular plasticity as a driving force in cancer initiation, progression, and therapy resistance, with insights into how tumour suppressors, infection, and environmental stress shape cellular identity. Together, these reflections highlight how decades of curiosity-driven research have helped define modern cancer biology.

🔗 Access transcripts for all our episodes at magazine.eacr.org/podcast

Professor Bernhard Küster, keynote speaker at EACR 2026, talks about his scientific journey from chemistry to chemical proteomics and precision medicine. He reflects on how an interdisciplinary mindset - combining chemistry, biology, and computational science - has shaped his approach to understanding how drugs act on proteins and how this knowledge can inform personalised cancer treatments. He also shares practical advice for early-career researchers on how to embrace interdisciplinarity in their work.

Bernhard discusses his team’s pioneering work developing technologies such as Prosit, Decrypt-E and Decrypt-M, and highlights how artificial intelligence is accelerating discoveries in proteomics. He also underscores the vital role of the clinical community in providing well-annotated tumour samples - an essential foundation for meaningful AI-driven cancer research.

🔗 Access transcripts for all our episodes at magazine.eacr.org/podcast